GLP-1 & compounded medication availability in Florida (2026)
Florida is a clean, baseline state for telehealth-prescribed compounded medications: standard pharmacy registration, a telehealth framework with its own out-of-state provider path, and no medication-specific surprises. Here is the full ten-line picture for Florida addresses, including the two lines we honestly do not carry.
Florida availability, product line by product line
| Product line | Available in Florida? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Second-largest baseline market in our pilot. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same flat price as every state. |
| NAD+ | Yes | 8–10 business days | Ordered through the standard online flow. |
| Sermorelin | Yes | 8–10 business days | Fulfilled by registered partner pharmacies. |
| Glutathione | No | N/A | OrderlyMeds does not carry this today. |
| BPC-157 | Yes | 8–10 business days | Available from us; section below. |
| TB-500 | Yes | 8–10 business days | In our catalog as a compounded injectable; details below. |
| KPV | No | N/A | Not something we dispense, injectables only. |
| Epitalon | Yes | 8–10 business days | Dispensed as a compounded injectable; see its section. |
| MOTS-c | Yes | 8–10 business days | Available as a compounded injectable; its own federal record follows. |
Reviewed November 16, 2026. If a line ever moves from No to Yes, it will be because the data behind this page changed, never because the copy did.
The research-peptide picture for Florida
Florida residents searching for these five peptides deserve the straight answer: OrderlyMeds sells four of them, BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable, and sells KPV in no state at all, because that line is not compounded as an injectable. What we can also give you is the accurate federal picture. Each section pairs FDA’s safety position on that specific substance with the compounding pathway that currently covers it, both cited and dated, on every one of the five regardless of whether it ships. The five records are not the same record, so we state them one line at a time.
BPC-157 in Florida
Sold by OrderlyMeds to Florida addresses as a compounded injectable, under a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Florida
Florida orders for TB-500 are something we take: the line is in our catalog as a compounded injectable.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Florida
No KPV through OrderlyMeds, in Florida or beyond, because the line is not compounded as an injectable and injectables are what we carry.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Florida
Epitalon is available from OrderlyMeds as a compounded injectable, Florida included.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Florida
MOTS-c is available from OrderlyMeds as a compounded injectable, Florida included. The federal picture below belongs to this line alone and differs from the four preceding it.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Florida’s pharmacy regulators say about compounded medications
Florida’s approach mirrors the federal one: compounding is governed through practice standards for pharmacies rather than category-by-category positions on individual medications. For patients, the operative facts are about registration: of the pharmacy shipping the order, and of the provider writing the prescription.
Florida regulates pharmacy compounding through board rules on compounding practice standards; no GLP-1-specific or peptide-specific prohibition has been published by the board. Source: Florida Board of Pharmacy.
Out-of-state pharmacies dispensing to Florida patients must register with the state as nonresident pharmacies. Source: Florida Board of Pharmacy.
Florida's telehealth framework permits licensed providers (including registered out-of-state telehealth providers) to prescribe via telehealth within the standard of care. Source: Center for Connected Health Policy (CCHP) Policy Finder.
Day to day, a Florida order looks identical to one from any baseline state: online evaluation, a provider authorized for Florida, fulfillment by a registered pharmacy, tracking to your door inside the published 8–10 business-day window. The price is the same flat national price at every dose. Florida pays what Montana pays.
Florida availability FAQs
Is compounded tirzepatide available in Florida?
Yes. OrderlyMeds ships compounded tirzepatide (our GLP-1/GIP line) to Florida addresses, at the same flat price charged in every state.
Does Florida treat telehealth prescriptions differently?
Florida runs its own registration path for out-of-state telehealth providers; the cited detail is in the regulator section above. Practically, OrderlyMeds’ standard online flow works for Florida addresses.
Can Floridians buy BPC-157 or Epitalon through OrderlyMeds?
Yes, both, as compounded injectables, in Florida and in every state we serve. TB-500 and MOTS-c as well. The one exception on this page is KPV, which is in no state’s formulary for us. Each section above gives the full, cited federal status for all five, line by line.
What is the delivery time to Florida?
8–10 business days from signup is the published window, with tracking emailed as soon as it exists.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
